Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands

References

• Levy BT, Graber MA. Respiratory syncytial virus infection in infants and young children. J Fam Pract 1997;45:473-81.
   PubMed Web of Science ®Google Scholar
• Ottolini M, Hemming V. Prevention and treatment recommendations for respiratory syncytial virus infection. Drugs 1997;54: 867-84.
   PubMed Web of Science ®Google Scholar
• Simoes E. Respiratory syncytial virus infection. Lancet 1999;354: 847-52.
   PubMed Web of Science ®Google Scholar
• Hall C. Respiratory syncytial virus. In: Feigin R, Cherry J, eds. Infectious Diseases. Philadelphia: W.B. Saunders, 1998.
   Google Scholar
• Canfield S, Simoes E. Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab. Pediatr Ann 1999;28:507-14.
   PubMed Web of Science ®Google Scholar
• Smyth RL, Openshaw PJ. Bronchiolitis. Lancet 2006;368:312-22.
   PubMed Web of Science ®Google Scholar
• Rothbarth PH, Kimpen JL, Roord JJ, Neijens HJ. Respiratory syncytial virus infections and preventive options. Ned Tijdschr Geneeskd 2000;144:15-19.
   PubMedGoogle Scholar
• Brandenburg AH, Jeannet PY, Steensel-Moll HA, Local variability in respiratory syncytial virus disease severity. Arch Dis Child 1997;77:410-14.
   PubMed Web of Science ®Google Scholar
• Malhotra A, Krilov L. Influenza and respiratory syncytial virus. Update on infection, management and prevention. Pediatr Clin North Am 2000;47:353-72.
   PubMed Web of Science ®Google Scholar
• Welliver R, Duffy L. The relationship of RSV-specific immunoglobulin E antibody responses in infancy, recurrent wheezing and pulmonary functions at age 7-8 years. Pediatr Pulmonol 1993;15:19-27.
   PubMed Web of Science ®Google Scholar
• Sigurs N, Bjarnason R, Sigurbergsson F, Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 1995;95:500-5.
   PubMed Web of Science ®Google Scholar
• Sampalis JS. Morbidity and mortality after RSV-associated hospitalisations among premature Canadian infants. J Pediatr 2003;143(5 Suppl):S150-6.
   PubMed Web of Science ®Google Scholar
• Greenough A, Cox S, Alexander J, Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child 2001;85:463-8.
   PubMed Web of Science ®Google Scholar
• Bont L, Steijn M, van Aalderen WM, Kimpen JL. Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. Pediatr Infect Dis J 2004;23:414-17.
   PubMed Web of Science ®Google Scholar
• Greenough A, Alexander J, Burgess S, Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004;89:673-8.
   PubMed Web of Science ®Google Scholar
• Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995;126:212-19.
   PubMed Web of Science ®Google Scholar
• Rodriguez WJ, Parrott RH. Ribavirin aerosol treatment of serious respiratory syncytial virus infection in infants. Infect Dis Clin North Am 1987;1:425-39.
   PubMedGoogle Scholar
• Rietveld E, De Jonge HC, Polder JJ, Anticipated costs of hospitalisation for respiratory syncytial virus infection in young children at risk. Pediatr Infect Dis J 2004;23:523-9.
   PubMed Web of Science ®Google Scholar
• Miedema CJ, Kors AW, Ten WE, Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in the Netherlands. Pediatr Infect Dis J 2001;20:160-3.
   PubMed Web of Science ®Google Scholar
• The European Medicines Agency. Available at: http://www.emea.eu.int/index/indexh1.htm.
   Google Scholar
• The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
   PubMed Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meissner HC, Palivizumab prophylaxis reduces hospitalisation due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40.
   PubMed Web of Science ®Google Scholar
• Weinstein MC Fineberg HV. Clinical Decision Analysis. Philadelphia: WB Saunders, 1980;228-65.
   Google Scholar
• Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007;25:55-71.
   PubMed Web of Science ®Google Scholar
• Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH. Handleiding voor kostenonderzoek; Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg [Manual for costing: methods and standard costs for economic evaluations in health care]. Actualised version 2004. Diemen: College voor Zorgverzekeringen.
   Google Scholar
• College Tarieven Gezondheidszorg (CTG). Tarieflijst instellingen 2004. Utrecht: CTG.
   Google Scholar
• Riteco JA, Heij LJM de, Luijn JCF van, Wolff I. Richtlijnen voor farmaco-economisch onderzoek. College voor zorgverzekeringen 1999 : Amstelveen. CURE/cuo.228/2.
   Google Scholar
• Groothuis JR, Simoes EA, Levin MJ, Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993;329:1524-30.
   PubMed Web of Science ®Google Scholar
• The PREVENT Study Group. Reduction of RSV hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997;99:93-9.
   PubMed Web of Science ®Google Scholar
• Simoes EA, Sondheimer HM, Top FHJr, Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998;133:492-9.
   PubMed Web of Science ®Google Scholar
• Cabalka A. Physiological risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Pediatr Infect Dis J 2004;23:S41-5.
   PubMed Web of Science ®Google Scholar
• Centraal Bureau voor de Statistiek. Voor burg, 2005.
   Google Scholar
• Wren C, O'Sullivan JJ. Survival with congenital heart disease and need for follow up in adult life. Heart 2001;85:438-43.
   PubMed Web of Science ®Google Scholar
• Rietveld E, Steyerberg E, Ploder J, Passive immunisation against respiratory syncytial virus: a cost-effectiveness study. Chapter 32. Thesis: 60-69.
   Google Scholar
• Hoogendoorn EJI, Feenstra TL, Rutten-van Mölken MPMH. Inventarisatie van het gebruik en de kosten van zorg voor astma en COPD in Nederland. RIVM rapport 2004 ;260604001.
   Google Scholar
• Simoes EAF, Carbonell-Estrany X, Kimpen J, Palivizumab use decreases risk of recurrent wheezing in preterm children. Eur Respir J 2004;24(Suppl) 48:212s.
   Google Scholar
• Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2years of age in a defined geographical area. Arch Dis Child 2003;88:1065-9.
   PubMed Web of Science ®Google Scholar
• Roeckl-Wiedmann I, Liese JG, Grill E, Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162:237-44.
   PubMed Web of Science ®Google Scholar
• Wegner S, Vann JJ, Liu G, Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Pediatrics 2004;114:1612-19.
   PubMed Web of Science ®Google Scholar
• Lofland JH, O'Connor JP, Chatterton ML, Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther 2000;22:1357-69.
   PubMed Web of Science ®Google Scholar
• Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004;114:1606-11.
   PubMed Web of Science ®Google Scholar
• Resch B, Gusenleitner W, Nuijten MJC, Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin Ther 2008;30:749-60.
   PubMed Web of Science ®Google Scholar